Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III vortioxetine vs placebo in major depressive disorder
jRCT2080222779Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline in MADRS total score at Week 8. Started Mar 2015; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080222779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222779.